Cancer Treatment Reviews
Volume 27, Issue 1 , Pages 19-33 , February 2001

Postoperative irradiation in endometrial cancer: still a matter of controversy

References 

    REFERENCES
  1. Bristow RE. Endometrial cancer. Curr Opin Oncol. 1999;11:388–393
  2. Partridge E, Jessup J, Donaldson E. 1996 Patient Care Evaluation Study (PCE) of cancer of the corpus uteri (NCDB), American College of Surgery [abstract]. Gynecol Oncol. 1999;72:445
  3. Gretz HFIII, Economos K, Husain A. The practice of surgical staging and its impact on adjuvant treatment recommendations in patients with stage I endometrial carcinoma. Gynecol Oncol. 1996;61:409–415
  4. Lybeert MLM, van Putten WLJ, Brolmann HAM, Coebergh JWW. Postoperative radiotherapy for endometrial carcinoma stage I. Wide variation in referral patterns but no effect on long-term survival in a retrospective study in south-east Netherlands. Eur J Cancer. 1998;34:586–590
  5. Corn B, Dunton CJ, Carlson JA, Xie Y, Valicenti RK. National trends in the surgical staging of corpus cancer: a pattern-of-practice survey. Obstet Gynecol. 1997;90:628–631
  6. Maggino T, Romagnolo C, Zola P, Sartori E, Landoni F, Gadducci A. An analysis of approaches to the treatment of endometrial cancer in Western Europe: a CTF study. Eur J Cancer. 1995;31A:193–197
  7. Maggino T, Romagnolo C, Landoni F. An analysis of approaches to the management of endometrial cancer in North America: a CTF study. Gynecol Oncol. 1998;68:274–279
  8. Bliss P, Cowie VJ. Endometrial carcinoma: does the addition of intracavitary vault caesium to external beam therapy postoperatively result in improved control or increased morbidity?. Clin Oncol. 1992;4:373–376
  9. Descamps P, Calais G, Moire C. Predictors of distant recurrence in clinical stage I or II endometrial carcinoma treated by combination surgical and radiation therapy. Gynecol Oncol. 1997;64:54–58
  10. Fanning J, Nanavati PJ, Hilgers RD. Surgical staging and high dose rate brachytherapy for endometrial cancer: limiting external radiotherapy to node-positive tumors. Obstet Gynecol. 1996;87:1041–1044
  11. Wolfson AH, Sightler SE, Markoe AM. The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol. 1992;45:142–146
  12. Lewandowsky G, Torrisi J, Potkul RK. Hysterectomy with extended surgical staging and radiotherapy versus hysterectomy alone and radiotherapy in stage I endometrial cancer. Gynecol Oncol. 1990;36:401–404
  13. Carey MS, O’Connel GJ, Johanson CR. Good outcome associated with standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium. Gynecol Oncol. 1995;57:138–144
  14. Meerwaldt JH, Hoekstra JM, van Putten WLJ, Subandono Tjokrowardojo AJ, Koper PCM. Endometrial adenocarcinoma, adjuvant radiotherapy tailored to prognostic factors. Int J Radiat Oncol Biol Phys. 1990;18:299–304
  15. Maneschi M, Maneschi F, Geraci P. Surgical pathological staging of endometrial carcinoma and results of treatment. Eur J Gynaecol Oncol. 1992;13:30–35
  16. Ball HG. Do we know the best therapy for early endometrial cancer? [editorial]. Gynecol Oncol. 1996;60:173–175
  17. Laborde, S. La curie therapie des cancer. Paris, Masson, 1925, 234, 235
  18. Rotman M, Aziz H, Halpern J. Endometrial carcinoma: Influence of prognostic factors on radiation management. Cancer. 1993;71:1471–1479
  19. Maingon P, Mnold L, Magnin V. Preoperative radiotherapy and surgery for endometrial carcinoma: prognostic significance of the sterilisation of the specimen. Int J Radiat Oncol Biol Phys. 1998;41:551–557
  20. Menczer J, Krissi H, Chetrit A. The effect of diagnosis and treatment delay on prognostic factors and survival in endometrial carcinoma. Am J Obstet Gynecol. 1995;173:774–778
  21. Bolla M, de Carnulier J, Berland E. Pathologic prognostic factors in a series of 137 stage I TNM/UICC endometrial carcinomas. Radiother Oncol. 1999;53:209–211
  22. Gusberg SB, Yannopoulos D. Therapetic decisions in corpus cancer. Am J Obstet Gynecol. 1964;83:157
  23. Price JJ, Hahn GA, Rominger CJ. Vaginal involvement in endometrial carcinoma. Am J Obstet Gynecol. 1965;91:1060–1065
  24. Stander RW. Vaginal metastases following treatment of endometrial carcinoma. Am J Obstet Gynecol. 1956;71:776
  25. Sant Cassia LJ, Weppelmann B, Shingleton H, Soong SJ, Hatch K, Salter MM. Management of early endometrial carcinoma. Gynecol Oncol. 1989;35:362–366
  26. Rose PG. Endometrial carcinoma. New Engl J Med. 1996;335:640–649
  27. Gynecol Oncol. 1989;35:125–127
  28. ACOG Technical Bulletin. 1991;
  29. Jereczek-Fossa B, Badzio A, Jassem J. Surgery followed by radiotherapy in endometrial cancer: analysis of survival and patterns of failure. Int J Gynecol Cancer. 1999;9:285–294
  30. Petereit DG, Tannehill SP, Grosen EA, Martenbach EM, Schink JC. Outpatient vaginal cuff brachytherapy for endometrial cancer. Int J Gynecol Cancer. 1999;9:456–462
  31. Kucera H, Vavra N, Weghaupt K. Benefit of external irradiation in pathologic stage I endometrial carcinoma; a prospective clinical trial of 605 patients who received postoperative vaginal irradiation and additional pelvic irradiation in the presence of unfavorable prognostic factors. Gynecol Oncol. 1990;38:99–104
  32. Weiss E, Hirnle P, Hess CF, Bamberg M. Therapeutic outcome and relation of acute and late side effects in the adjuvant radiotherapy of endometrial carcinoma stage I and II. Radiother Oncol. 1999;53:37–44
  33. Weiss E, Hirnle P, Hess CF, Bamberg M. Adjuvant vaginal high-dose-rate afterloading alone in endometrial carcinoma: Patterns of relapse and side effects following low-dose therapy. Gynecol Oncol. 1998;71:72–76
  34. Zaino RJ, Kurman RJ, Diana KL, Morrow CP. Pathologic models to predict outcome for women with endometrial adenocarcinoma. Cancer. 1996;77:1115–1121
  35. Kaku T, Tsukamoto N, Hachisuga T. Endometrial carcinoma associated with hyperplasia. Gynecol Oncol. 1996;60:22–25
  36. Kasamatsu T, Shiromizu K, Takahashi M, Matsumoto K, Shirai T. Analysis of initial failure site and spread pattern in endometrial carcinoma: a Japanese experience. Int J Gynecol Cancer. 1999;9:470–476
  37. Ahmad NR, Lanciano RM, Corn BW, Schulthesis T. Postoperative radiation therapy for surgically staged endometrial cancer: impact of time factors (overall treatment time and surgery-to-radiation interval) on outcome. Int J Radiat Oncol Biol Phys. 1995;33:837–842
  38. Boz G, De Paoli A, Innocente R. Endometrial stage I carcinoma treated with surgery and adjuvant irradiation: a retrospective analysis. Tumori. 1995;81:256–260
  39. Corn BW, Lanciano RM, D’Agostino R. The relationship of local and distant failure from endometrial cancer: Defining a clinical paradigm. Gynecol Oncol. 1997;66:411–416
  40. MacLoad C, Fowler A, Duval P. High-dose-rate brachytherapy alone post-hysterectomy for endometrial cancer. Int J Radiat Oncol Biol Phys. 1998;42:1033–1039
  41. Weiss MF, Connell PP, Waggoner S, Rotmensch J, Mundt AJ. External pelvic radiation therapy in stage IC endometrial carcinoma. Gynecol: Obstet; 1999; p. 599–602
  42. Berclaz G, Hanggi W, Kratzer-Berger A. Lymphadenectomy in high risk endometrial carcinoma stage I and II: no more morbidity and no need for external pelvic radiation. Int J Gynecol Cancer. 1999;9:322–328
  43. Larson DM, Broste SK, Krawisz BR. Surgery without radiotherapy for primary treatment of endometrial cancer. Obstet Gynecol. 1998;91:355–359
  44. Greven KM, Corn BW, Case D, Purser P, Lanciano R. Which prognostic factors influence the outcome of patients with surgically staged endometrial cancer treated with adjuvant radiation?. Int J Radiat Oncol Biol Phys. 1997;39:413–418
  45. Algan O, Tabesh T, Hanlon A. Improved outcome in patients treated with postoperative radiation therapy for pathologic stage I/II endoemtrial cancer. Int J Radiat Oncol Biol Phys. 1996;35:925–933
  46. Corn BW, Lanciano RM, Greven KM. Impact of improved irradiation technique, age, and lymph node sampling on the severe complication rate of surgically staged endometrial cancer patients: a multivariate analysis. J Clin Oncol. 1994;12:510–515
  47. Bar-Am A, Ron IG, Kupermine M. The role of routine pelvic lymph node sampling in patients with stage I endometrial carcinoma: second thoughts. Acta Obstet Gynecol Scand. 1998;77:347–350
  48. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. Cancer. 1987;60:2035–2041
  49. Yokoyama Y, Maruyama H, Sato S, Saito Y. Indispensability of pelvic and paraaortic lymphadenectomy in endometrial cancer. Gynecol Oncol. 1997;64:411–417
  50. Morrow CP, Bundy BN, Kurman RJ. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991;40:55–65
  51. DiSaia PJ, Creasman WT, Boronow RC, Blessing JA. Risk factors and recurrence patterns in stage I endometrial cancer. Am J Obstet Gynecol. 1985;151:1009–1015
  52. Kamura T, Yahata H, Shigematsu T. Predicting pelvic lymph node metastasis in endometrial carcinoma. Gynecol Oncol. 1999;72:387–391
  53. Doering DL, Barnhill DR, Weiser EB, Burke TW. Woodward JE, Park RC. Intraoperative evaluation of depth of myometrial invasion in stage I endometrial adenocarcinoma. Obstet Gynecol. 1989;74:930–933
  54. Malviya VK, Deppe G, Malone JM, Sundareson AS, Lawrence WD. Reliability of frozen section examination in identifying poor prognostic indicators in stage I endoemtrial adenocarcinoma. Gynecol Oncol. 1989;34:299–304
  55. Patsner B, Mann WJ, Cohen H, Loesch M. Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma. Am J Obstet Gynecol. 1988;158:399–402
  56. Naumann RW, Higgins RV, Hall JB. The use of adjuvant radiation therapy by members of the Society of Gynecologic Oncologists. Gynecol Oncol. 1999;75:4–9
  57. Orr J. Surgical staging of endometrial cancer: does the patient benefit?. Gynecol Oncol. 1998;71:335–339
  58. Greven KM, Randall M, Fanning J. Patterns of failure in patients with stage I, grade 3 carcinoma of the endometrium. Int J Radiat Oncol Biol Phys. 1990;19:529–534
  59. Orr JW, Holimon JL, Orr PF. Stage I corpus cancer: is teletherapy necessary?. Am J Obstet and Gynecol. 1997;176:777–788
  60. Homesley HD, Kadar N, Barrett RJ, Lentz SS. Selective pelvic and para-aortic lymphadenectomy does not increase morbidity in surgical staging of endometrial carcinoma. Am J Obstet Gynecol. 1992;167:1225–1230
  61. Boronow RC. Surgical staging of endometrial cancer: evolution, evaluation, and responsible challenge—a personal perspective. Gynecol Oncol. 1997;66:179–189
  62. Creutzberg CL, van Putten WLJ, Koper PCM. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet. 2000;355:1404–1411
  63. Roberts DWT. Carcinoma of the body of the uterus at Chelsea Hospital for Women. 1943–1953. J Obstet Gynaecol Br Commonw. 1961;68:132–138
  64. Kilgore LC, Partridge EE, Alvarez RD. Adenocarcinoma of the endometrium: survival comparison of patients with and without pelvic node sampling. Gynecol Oncol. 1995;56:29–33
  65. Mohan DS, Samuels A, Selmin MA. Long-term outcomes of therapeutic pelvic lymphadenectomy for stage I endometrial adenocarcinoma. Gynecol Oncol. 1998;70:165–171
  66. Faught W, Krepart GV, Lotocki R, Heywood M. Should selective paraaortic lymphadenectomy be part of surgical staging for endometrial cancer?. Gynecol Oncol. 1994;55:51–55
  67. Cardenes H, Randall ME. Clarity and confusion regarding adjuvant radiation therapy in early endometrial cancer [editorial]. Gynecol Oncol. 1999;75:1–3
  68. Pettersson, F. Annual report on the results of treatment in gynecological cancer. Stockholm, International Federation of Gynecology and Obstetrics, 1996, 22
  69. Schorge JO, Molpus KL, Goodman A, Nikrui N, Fuller AF. The effect of postsurgical therapy on stage III endometrial carcinoma. Gynecol Oncol. 1996;63:34–39
  70. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Obstet Gynecol. 1980;56:419–426
  71. Ayhan A, Tuncer ZS, Tuncer R. Risk factors for recurrence in clinically early endometrial carcinoma: an analysis of 183 consecutive cases. Eur J Obstet Gynecol. 1994;57:167–170
  72. Lybeert MLM, van Putten WLJ, Ribot JG, Crommelin MA. Endometrial carcinoma: high dose-rate brachytherapy combination with external irradiation; a multivariate analysis of relapses. Radiother Oncol. 1989;16:245–252
  73. Hoffman K, Nekhlyudov L, Deligdisch L. Endometrial carcinoma in elderly women. Gynecol Oncol. 1995;58:198–201
  74. Ito K, Watanabe K, Nasim S. K- ras point mutations in endometrial carcinoma: Effect on outcome is dependent on age of patient. Gynecol Oncol. 1996;63:224–238
  75. Lindahl B, Einarsdottir M, Iosif C, Ranstam J, Willen R. Endomerial carcinoma: Results of primary surgery on FIGO stages Ia-Ic and predictive value of histopathological parameters. Anticancer Res. 1997;17:2297–2302
  76. Kodama S, Kase H, Tanaka K, Matsui K. Multivariate analysis of prognostic factors in patients with endometrial cancer. Int J Gynecol Obstet. 1996;53:23–30
  77. Fanning JDO, Alvarez PM, Tsukada Y, Piver MS. Prognostic significance of the extent of cervical involvement by endometrial cancer. Gynecol Oncol. 1991;40:46–47
  78. Tornos C, Silva EG, El-Naggar A, Burke TW. Aggressive stage I grade 1 endometrial carcinoma. Cancer. 1992;70:790–798
  79. Hamel NW, Sebo TJ, Wilson TO. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Gynecol Oncol. 1996;62:192–198
  80. Kadar NR, Malfetano JH, Homesley HD. Steroid receptor concentrations in endometrial carcinoma; effect on survival in surgically staged patients. Gynecol Oncol. 1993;50:281–286
  81. Fukuda K, Mori M, Uchiyama M, Iwai K, Wasaka T, Sugimori H. Prognostic significance of progesterone receptor immunochistochemistry in endometrial carcinoma. Gynecol Oncol. 1998;69:220–225
  82. Boente MP, Yordan EL, Mcintosh DG. Prognostic factors and long-term survival in endometrial adenocarcinoma with cervical involvement. Gynecol Oncol. 1993;51:316–322
  83. Leminen A, Forss M, Lehtovirta P. Endometrial adenocarcinoma with clinical evidence of cervical involvement: accuracy of diagnostic procedures, clinical course, and prognostic factors. Acta Obstet Gynecol Scand. 1995;74:61–66
  84. Mayr NA, Wen B, Benda JA. Postoperative radiation therapy in clinical stage I endometrial cancer: corpus, cervical, and lower uterine segment involvement—patterns of failure. Radiology. 1995;196:323–328
  85. Lanciano RM, Curran WJ, Greven KM. Influence of grade, histologic subtype, and timing of radiotherapy on outcome among patients with stage II carcinoma of the endometrium. Gynecol Oncol. 1990;39:368–373
  86. Abeler V, Kjorstad KE. Serous papillary carcinoma of the endometrium: A histopathological study of 22 cases. Gynecol Oncol. 1990;39:266–271
  87. Lax SF, Kendall B, Tashiro H, Slebos RJC, Hedrick Ellenson L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma. Cancer. 2000;88:814–824
  88. Barhum M, Stein M, Rosenblatt E, Dale J, Kuten A. Pathological stage I endometrial carcinoma: the role for adjuvant radiotherapy. Tumori. 1993;79:405–409
  89. Abeler V, Kjorstad KE. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. Gynecol Oncol. 1991;40:207–217
  90. Abeler V, Kjorstad KE, Nesland JM. Undifferentiated carcinoma of the endometrium: A histopathologic and clinical study of 31 cases. Cancer. 1991;68:98–105
  91. Am J Obstet Gynecol. 1996;174:529–534
  92. Geisler JP, Geisler HE, Miller GA, Wiemann MC, Zhou Z, Crabtree W. MIB-1 in endoemtrial carcinoma: prognostic significance with 5-year follow-up. Gynecol Oncol. 1999;75:432–436
  93. Garzetti GG, Ciavattini A, Goteri G, De Nictolis M, Romanini C. Proliferating cell nuclear antigen in endoemtrial carcinoma: pretreatment identification of high-risk patients. Gynecol Oncol. 1996;61:16–21
  94. Nazeer T, Ballouk F, Malfetano JH, Figge H, Ambros RA. Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/ neu expression. Am J Gynecol Oncol. 1995;173:829–834
  95. Geisler JP, Wiemann MC, Zhou Z, Miller GA, Geisler HE. p53 as a prognostic indicator in endometrial cancer. Gynecol Oncol. 1996;61:245–248
  96. Kohlberger P, Gitsch G, Loesch A. p53 protein overexpression in early stage endometrial cancer. Gynecol Oncol. 1996;62:213–217
  97. Susini T, Baldi F, Howard CM. Expression of the retinoblastoma-related gene Rb2/p130 correlates with clinical outcome in endometrial cancer. J Clin Oncol. 1998;16:1085–1093
  98. Caduff RF, Johnston CM, Svoboda-Newman SM, Poy EL, Merajver SD, Frank TS. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol. 1996;148:1671–1678
  99. Heatley MK. Association between the apoptotic index and established prognostic parameters in endometrial adenocarcinoma. Histopathol. 1995;27:469–472
  100. Fishman DA, Roberts KB, Chambers JT. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma of the endometrium. Gynecol Oncol. 1996;61:189–196
  101. Grigsby PW, Perez CA, Kuten A. Clinical stage I endometrial cancer: results of adjuvant irradiation and patterns of failure. Int J Radiat Oncol Biol Phys. 1991;21:379–385
  102. Bedwinek J, Galakatos A, Camel M. Stage I, grade III adenocarcinoma of the endometrium treated with surgery and irradiation. Cancer. 1984;54:40–47
  103. Rantanen V, Grenman S, Kulmala J. Radiation sensivity of endometrial carcinoma in vitro. Gynecol Oncol. 1992;44:217–222
  104. Elliott P, Green D, Coates A. The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer. Int J Gynecol Cancer. 1994;4:84–93
  105. Nori D, Hilaris BS, Tome M, Lewis JL, Birnbaum S, Fuks Z. Combined surgery and radiation in endometrial carcinoma: an analysis of prognostic factors. Int J Radiat Oncol Biol Phys. 1987;13:489–497
  106. Piver MS, Hempling RE. A prospective trial of postoperative vaginal radium/cesium for grade 1–2 less than 50% myometrial invasion and pelvic radiation therapy for grade 3 or deep myometrial invasion in surgical stage I endometrial adenocarcinoma. Cancer. 1990;66:1133–1138
  107. Podczaski E, Kaminski P, Gurski K. Detection and patterns of treatment failure in 300 consecutive cases of ‘early’ endometrial cancer after primary surgery. Gynecol Oncol. 1992;47:323–327
  108. Chen SS. Operative treatment in stage I endometrial carcinoma with deep myometrial invasion and/or grade 3 tumor surgically limited to the corpus uteri. No recurrence with only primary surgery. Cancer. 1989;63:1843–1845
  109. Roberts JA, Brunetto VL, Keys HM. A phase III randomized study of surgery versus surgery plus adjunctive radiation therapy in intermediate-risk endometrial carcinoma (GOG 99) [abstract] Society of Gynecologic Oncologists, 99thAnnual Meeting,. 1998; p. 70
  110. Podratz K, Mariani A, Webb M. Staging and therapeutic value of lymphadenectomy in endometrial cancer. Gynecol Oncol. 1998;70:163–164
  111. Jereczek-Fossa B, Badzio A, Jassem J. Recurrent endometrial cancer after surgery alone: results of salvage radiotherapy. Int J Radiat Oncol Biol Phys. 2000;48:405–413
  112. Carl UM, Bahsen J, Edel B, Chandra A. The value of a postoperative radiation therapy in FIGO stage I and II endometrial cancers. Strahlenther Onkol. 1995;171:322–325
  113. Rush S, Gal D, Potters L, Bosworth J, Lovecchio J. Pelvic control following external beam irradiation for surgical stage I endometrial adenocarcinoma. Int J Radiat Oncol Biol Phys. 1995;33:851–854
  114. Stryker JA, Podczaski E, Kaminski P, Velkley DE. Adjuvant external beam therapy for pathologic stage I and occult stage II endometrial carcinoma. Cancer. 1991;67:2872–2879
  115. Torrisi JR, Barnes WA, Popescu G. Postoperative adjuvant external-beam radiotherapy in surgical stage I endometrial carcinoma. Cancer. 1989;64:1414–1417
  116. Eltabbakh GH, Piver MS, Hempling RE, Shin KH. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial. Int J Radiat Oncol Biol Phys. 1997;38:373–380
  117. Hansgen G, Nagel M, Dunst J, Enke H. Postoperative radiotherapy in endometrial carcinoma. A retrospective analysis of 541 cases. Strahlenther Onkol. 1999;175:54–553
  118. Jereczek-Fossa B, Jassem J, Nowak R. Late complications after postoperative radiotherapy in endometrial cancer: analysis of 317 consecutive cases with application of linear-quadratic model. Int J Radiat Oncol Biol Phys. 1998;41:329–338
  119. Kloetzer KH, Gunther R, Wendt T. The vaginal stump recurrence rate in endoemtrial carcinoma in relation to the target volume of paotoerative HDR-afterloading brachytherapy. Strahlenther Onkol. 1997;173:13–17
  120. Anderson JM, Stea B, Hallum AV. High-dose rate postoperative vaginal cuff irradiation alone for stage IB and IC endometrial cancer. Int J Radioat Oncol Biol Phys. 2000;46:417–425
  121. Randall ME, Wilder J, Greven K, Raben M. Role of intracavitary cuff boost after adjuvant external irradiation in early endometrial carcinoma. Int J Radiat Oncol Biol Phys. 1990;19:49–54
  122. Burke TW, Gershenson DM, Morris M. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma. Gynecol Oncol. 1994;55:47–50
  123. Marchetti DL, Caglar H, Driscoll DL, Hreshchyshyn MM. Pelvic radiation in stage I endometrial adenocarcinoma with high-risk attributes. Gynecol Oncol. 1990;37:51–54
  124. Pettersson B, Jansson H, Nilsson A, Schmidt M, Stenson S. Prophylactic vaginal irradiation with low dose rate afterloading technique in women with endometrial cancer [abstract]. In:  Mould RF editors. Brachytherapy 2. Leersum: Nucletron International BV; 1989;p. 240–244
  125. Stokes S, Bedwinek J, Breaux S, Kao M, Camel M, Perez CA. Treatment of stage I adenocarcinoma of the endoemtrium by hysterectomy and irradiation: analysis of complications. Obstet Gynecol. 1985;65:86–92
  126. Greven KM, D’Agostino RB, Lanciano RM, Corn BW. Is there a role for a brachytherapy vaginal boost in the adjuvant management of patients with uterine-confined endometrial cancer?. Int J Radiat Oncol Biol Phys. 1998;42:101–104
  127. Lanciano RM, Corn BW, Schultz DJ. The justification for a surgical staging system in endoemtrial cancer. Radiother Oncol. 1993;28:189–196
  128. Wang CC. The vanishing role of preoperative radiation therapy for stage I endometrial carcinoma. Int J Radiat Oncol Biol Phys. 1991;21:1095–1096
  129. Ackerman I, Malone S, Thomas G. Endometrial carcinoma—relative effectiveness of adjuvant irradiation vs therapy reserved for relapse. Gynecol Oncol. 1996;60:177–183
  130. Sears JD, Greven KM, Hoen HM. Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer. Cancer. 1994;74:1303–1308
  131. Hoestra CJM, Koper PCM, van Putten WLJ. Recurrent endometrial adenocarcinoma after surgery alone: prognostic factors and treatment. Radiother Oncol. 1993;27:164–166
  132. Stringer CA, Gershenson DM, Burke TW, Edwards CL, Gordon AN, Wharton JT. Adjuvant chemotherapy with cisplatin, doxorubicin and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: a preliminary analysis. Gynecol Oncol. 1990;38:305–308
  133. Morrow CP, Bundy BN, Homesley HD. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group study. Gynecol Oncol. 1990;36:166–171
  134. Greer BE, Hamberger AD. Treatment of intraperitoneal metastatic adenocarcinoma of the endometrium by the whole-abdomen moving strip technic and pelvic boost irradiation. Gynecol Oncol. 1983;16:365–367
  135. Potish RA, Twiggs LB, Adcock LL, Prem K. Role of whole abdominal radiation therapy in the management of endometrial cancer: prognostic importance of factors indicating peritoneal metastases. Gynecol Oncol. 1985;21:80–86
  136. Reisinger SA, Asbury R, Liao S-Y, Homesley HD. A phase I study of weekly cisplatin and whole abdominal radiation for the treatment of stage III and IV endometrial carcinoma: a Gynecologic Oncology Group pilot study. Gynecol Oncol. 1996;63:299–303
  137. Onda T, Yoshikawa H, Mizutani K. Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br J Cancer. 1997;75:1836–1841
  138. De Palo G, Mangioni C, Periti P, Del Vecchio M, Marubini E. Treatment of FIGO (1971) stage I endometrial carcinoma with intensive surgery, radiotherapy and hormonotherapy according to pathological prognostic groups. Long-term results of a randomised multicentre study. Eur J Cancer. 1993;29A:1133–1140
  139. Vergote I, Kjorstad K, Abelar V, Kolstad P. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer. 1989;64:1011–1016
  140. Peters LJ, Goepfert H, Ang KK. Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys. 1993;26:3–11
  141. Nag S, Abitbol A, Anderson LL. Consensus guidelines for high dose rate remote brachytherapy in cervical, endometrial, and endobronchial tumors. Int J Radiat Oncol Biol Phys. 1993;27:1241–1244
  142. Withers HR, Thames HD, Peters LJ. A new isoeffect curve for change in dose per fraction. Radiother Oncol. 1983;1:187–191
  143. Borger JH, Kemperman H, Smitt HS. Dose and volume effects on fibrosis after breast conservation therapy. Int J Radiat Oncol Biol Phys. 1994;30:1073–1081
  144. Newman G. Increased morbidity following the introduction of remote afterloading, with increased dose rate, for cancer of the cervix. Radiother Oncol. 1996;39:97–103
  145. Sarkaria JN, Petereit DG, Stitt JA. A comparison of the efficacy and the complication rates of low dose-rate versus high dose-rate brachytherapy in the treatment of the uterine cervical carcinoma. Int J Radiat Oncol Biol Phys. 1994;30:75–82
  146. Orton CG. High dose rate versus low dose rate brachytherapy for gynecological cancer. Sem Radiat Oncol. 1993;4:232–239
  147. Maciejewski B, Withers HR, Taylor JM, Hliniak A. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation. Int J Radiat Oncol Biol Phys. 1989;16:831–843
  148. Fowler JF, Lindstrom MJ. Loss of control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys. 1992;23:457–467
  149. Lanciano RM, Pajak TF, Matrz K, Hanks GE. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study. Int J Radiat Oncol Biol Phys. 1993;25:391–397
  150. Sismondi P, Sinistrero G, Zola P. Complications of uterine cervix carcinoma treatment: the problem of a uniform classification. Radiother Oncol. 1989;14:9–17
  151. Snijders-Keilholz A, Stork M, Davelaar J, Hermans J, Leer JWH. Endometrial carcinoma, results of combined surgery and radiotherapy treatment of 93 patients. Eur J Obste Gynecol Reprod Biol. 1990;36:125–135
  152. Morris M, Alvarez RD, Kinney WK, Wilson TO. Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol Oncol. 1996;60:288–291
  153. Pierga J–Y, Dieras V, Paraiso D. Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin and 5-fluorouracil: a phase II study. Gynecol Oncol. 1996;60:59–63
  154. Schunemann H, Jourdain M. Double and triple neoplasms in endometrial carcinoma. Zentralbl Gynakol. 1994;116:522–526
  155. Bucy GS, Mendenhall WM, Morgan LS. Clinical stage I and II endometrial carcinoma treated with surgery and/or radiation therapy: analysis of prognostic and treatment-related factors. Gynecol Oncol. 1989;33:290–295
  156. Tiitinen A, Forss M, Aho I, Vesterinen E, Nieminen U. Endometrial adenocarcinoma: Clinical outcome in 881 patients and analysis of 146 patients whose deaths were due to endometrial cancer. Gynecol Oncol. 1986;25:11–19
  157. Reisinger SA, Staros EB, Feld R, Mohiuddin M, Lewis GC. Preoperative radiation therapy in clinical stage II endometrial carcinoma. Gynecol Oncol. 1992;45:174–178
  158. Straughn JM, Stringer J, Barnes MN, Partidge EE, Alvarez RD, Kilgore L. Choosing the appropriate treatment for endometrial adenocarcinoma: a cost effectiveness analysis [abstract]. Gynecol Oncol. 2000;76:251
  159. Fanning J, Firestein SL. Cost-effective analysis of complete lymphadenectomy and brachytherapy in early endometrial cancer [abstract]. Gynecol Oncol. 2000;76:128
  160. Konski AA, Bracy PM, Jurs SG, Weiss SJ, Zeidner SR. Cost minimization analysis of various treatment options for surgical stage I endometrial carcinoma. Int J Radiat Oncol Biol Phys. 1997;37:367–373

PII: S0305-7372(00)90195-6

doi: 10.1053/ctrv.2000.0195

Cancer Treatment Reviews
Volume 27, Issue 1 , Pages 19-33 , February 2001

Article Tools